Comparing the current results to its competitors, Merus N V reported Revenue increase in the 3 quarter 2025 by 3.21 % year on year. The revenue growth was below Merus N V 's competitors' average revenue growth of 4.89 %, achieved in the same quarter.
Overall company revenue, grew less, than total company revenues, at 3.21 % and company approximately market share, declined to 0.09 %. << More on MRUS Market Share.
*Market share is calculated based on total revenue.
July 24, 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 3, 2024 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in multispecific antibodies, is making significant strides in the oncology landscape with recent announcements that underscore its commitment to innovation and patient outcomes.Merus has disclosed that the first patient has been dosed in its Phase 3 LiGeR-HN2 trial, evaluating Petosemtamab in the second and third line (2/3L) treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC). As confirmed following feedback from the U.S. Food and Drug Administration (FDA), Petosemtamab will be administered at a dosage of 1500 mg every two weeks (Q2W) for ...
May 14, 2024
Cyprus has joined the ranks of European countries endorsing the use of bioinsecticides, issuing emergency use authorization for Vestaron s SPEAR LEP bioinsecticide. This authorization makes Cyprus the third country within the European region permitting the use of this peptide-based bioinsecticide, designed to combat Tomato Leafminer, a destructive pest that significantly reduces crop yields.This milestone demonstrates a growing reliance on scientifically advanced, environmentally friendly solutions for pest control in the European agricultural scene. The permission to use SPEAR LEP in Cyprus is expected to bring remarkable benefits to the local farmers by providing an efficient tool to maintain crop health a...
May 13, 2024
Utrecht, The Netherlands, and Cambridge, Mass. - Merus N.V. (Nasdaq: MRUS), a leading clinical-stage oncology company specializing in the development of innovative antibodies for cancer treatment, is thrilled to announce today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for their promising drug, petosemtamab. This designation signifies a major step forward in the quest to revolutionize the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for patients who no longer respond to conventional therapies.Petosemtamab, which falls under Merus innovative Biclonics and Triclonics antibody platforms, has shown remarkable efficacy...
International Stem Cell Corporation Share Performance
+182.93%
One Year
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Merus N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Merus N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
